The multiple sclerosis (MS) market is expected to peak at $18.3 billion in 2018, according to healthcare analysts Datamonitor Healthcare. An important drug used in the treatment of multiple sclerosis ended up triggering Perrigo Company’s blockbuster acquisition of Elan Corp., according to terms of the agreement announced Monday by officials of both operations. Tysabri sales are growing at a 19-percent compound annual rate. Tysabri, administered to MS patients to slow or halt effects of the incurable disease of the central nervous system, had global sales of $1.6 billion last year.
It is, in large part, what prompted Royal Pharma to attempt repeated hostile takeovers of Elan in the past four months. It’s also the biggest reason Perrigo entered the Elan sweepstakes, striking a $8.6 billion deal, including $6.7 billion in cash.
Read more
